This was observed in the TUBA study in a 42-year-old BRCA2 pathogenic variant carrier with a serous tubal intraepithelial carcinoma lesion in the fallopian tube and an invasive high-grade serous carcinoma at subsequent oophorectomy and staging surgery (Stage IA).10 Thus, missing a serous tubal intraepithelial carcinoma could expose a participant to high-stage tubo-ovarian cancer. The gene discussed is BRCA2; the disease is serous adenocarcinoma.